BioCentury
ARTICLE | Distillery Therapeutics

Cancer

December 5, 2018 1:30 PM UTC

Mouse studies suggest an oncolytic herpes simplex virus (HSV) expressing CDH1 could help treat glioblastoma multiforme (GBM). An oncolytic HSV was engineered to express human CDH1 to enhance cell-to-cell transmission and reduce viral clearance by NK cells. In allograft and xenograft mouse models of GBM, intratumoral injection of the CDH1-expressing oncolytic HSV decreased tumor growth and increased survival and viral titers in the brain compared with the unmodified HSV. Next steps could include testing the CDH1-expressing oncolytic HSV in other cancers.

Amgen Inc. markets Imlygic talimogene laherparepvec, a modified HSV type 1 (HSV-1) carrying the gene for granulocyte macrophage colony-stimulating factor (GM-CSF; CSF2), to treat melanoma...

BCIQ Company Profiles

Ohio State University

BCIQ Target Profiles

E-cadherin (CDH1) (CD324)